BO
BO1.F BioCryst Pharmaceuticals Inc
- Market cap
- EUR 1.77B
- P/E
- -
- P/B
- 55.19x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is BO1.F undervalued?
Graham numberThe Graham number of BioCryst Pharmaceuticals Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
BioCryst Pharmaceuticals Inc fundamental analysis
No fundamental analysis for BioCryst Pharmaceuticals Inc yet.
BioCryst Pharmaceuticals Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About BioCryst Pharmaceuticals Inc
BioCryst Pharmaceuticals, Inc., a biotechnology company, developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated and seasonal influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat HAE. It is also developing BCX17725, a protein therapeutic for netherton …
Full company profileBioCryst Pharmaceuticals Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
BioCryst Pharmaceuticals Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 26.4M | 25.2M | 20.7M | 48.8M | 17.8M | 157M | 271M | 331M | 451M | 875M | 740M |
| Gross Profit | 23.7M | 23.5M | 20.2M | 44.7M | 16.1M | 150M | 264M | 327M | 438M | 856M | 726M |
| Operating Income | -48.6M | -57.4M | -94.2M | -99.5M | -175M | -178M | -148M | -104M | -2.54M | 341M | 197M |
| EBITDA | - | -56.5M | -91.3M | -96.3M | -168M | -123M | -145M | -116M | 12.8M | 348M | -718M |
| Net Income | -55.1M | -65.8M | -101M | -109M | -183M | -184M | -247M | -227M | -88.9M | 264M | -807M |
| EPS | - | -0.67 | -0.92 | -0.71 | -1.03 | -1.02 | -1.32 | -1.10 | -0.43 | 1.24 | -3.15 |
| Balance Sheet | |||||||||||
| Total Assets | 89.8M | 178M | 147M | 175M | 335M | 588M | 550M | 517M | 490M | 514M | 591M |
| Total Liabilities | 88.3M | 94.5M | 97.6M | 137M | 354M | 695M | 845M | 972M | 966M | 633M | 988M |
| Shareholders' Equity | 1.58M | 83.8M | 49.2M | 38.3M | -1.02B | -1.21B | -1.45B | -456M | -476M | -119M | -397M |
| Cash & Short-term Investments | 22.1M | 50.3M | 26.7M | 114M | 272M | 504M | 305M | 111M | 105M | 89.7M | 97.0M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -53.4M | -41.1M | -92.6M | -89.6M | -135M | -142M | -162M | -110M | -52.0M | 347M | 101M |
| Capital Expenditure | 5.28M | 328K | 366K | 343K | 514K | 2.39M | 1.35M | 2.14M | 1.12M | 2.47M | 1.13M |
| Free Cash Flow | - | -41.5M | -92.9M | -89.9M | -138M | -145M | -163M | -112M | -53.1M | 345M | 99.6M |
| Ratios | |||||||||||
| ROE | -3,494.6% | -78.5% | -205.7% | -284.7% | - | - | - | - | - | - | - |
| ROA | -61.4% | -36.9% | -69.0% | -62.1% | -54.6% | -31.3% | -44.9% | -43.8% | -18.1% | 51.3% | -136.6% |
| Net Profit Margin | -209.3% | -261.2% | -490.3% | -223.0% | -1,026.4% | -117.1% | -91.2% | -68.4% | -19.7% | 30.2% | -109.1% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
BioCryst Pharmaceuticals Inc dividends
BioCryst Pharmaceuticals Inc has not paid dividends in the last 9 fiscal years.
Who owns BioCryst Pharmaceuticals Inc
- Insiders 1.27%
- Institutions 98.73%
- Public & others 0.00%
- Shares outstanding 257M
- Free float 224M
BioCryst Pharmaceuticals Inc company profile
- Company name
- BioCryst Pharmaceuticals Inc
- Ticker
- BO1.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 435
- Fiscal year end
- December
- Address
- 4505 Emperor Boulevard, Durham, NC, United States, 27703
- Phone
- 919 859 1302
- Website
- biocryst.com
About BioCryst Pharmaceuticals Inc
BioCryst Pharmaceuticals, Inc., a biotechnology company, developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated and seasonal influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat HAE. It is also developing BCX17725, a protein therapeutic for netherton syndrome which is in phase 1; Avoralstat, an ocular plasma kallikrein inhibitor for diabetic macular edema that is in Phase 1; Navenibart, a monoclonal antibody plasma kallikrein inhibitor for HAE which is in Phase 3; BCX17725, an investigational protein therapeutic KLK5 inhibitor for the treatment of netherton syndrome that is in phase 1 clinical trial; STAR-0310, a monoclonal antibody OX40 antagonist for the treatment of atopic dermatitis which is in Phase 1a trial. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd., Shionogi & Co., Ltd., and Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
BioCryst Pharmaceuticals Inc management
10- Mr. Charles K. GayerCEO, President & Director · born 1971
- Mr. Babar GhiasCFO & Head of Corporate Development · born 1979
- Ms. Alane P. BarnesSenior VP, Chief Legal Officer & Corporate Secretary · born 1966
- Mr. John RueschChief Technical Operations Officer
- Dr. David W. Jenkins M.A., Ph.D.Chief Scientific Officer
- Nick WilderManager of Investor Relations
- Ms. Stephanie AngeliniChief People Officer & Communications Officer
- Dr. William P. Sheridan MBBSChief Development Officer · born 1955
- Dr. Yarlagadda S. Babu Ph.D.Chief Discovery Officer · born 1953
- Ms. Jinky Ang RosselliChief Data Innovation Officer